Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hims & Hers Health Inc
(NY:
HIMS
)
18.71
-0.32 (-1.71%)
Streaming Delayed Price
Updated: 1:25 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hims & Hers Health Inc
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
October 30, 2024
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's...
Via
Benzinga
Exposures
Product Safety
Smart Money Is Betting Big In HIMS Options
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 30, 2024
Via
Benzinga
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
October 30, 2024
Disrupting pharmacies is just the start for Hims & Hers.
Via
The Motley Fool
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
October 29, 2024
From
Hims & Hers
Via
Business Wire
A Look Into Hims & Hers Health Inc's Price Over Earnings
October 22, 2024
Via
Benzinga
How Is The Market Feeling About Hims & Hers Health?
October 22, 2024
Via
Benzinga
This Is What Whales Are Betting On Hims & Hers Health
October 21, 2024
Via
Benzinga
Top 3 Stocks Institutions Are Buying Right Now
October 28, 2024
Despite the stock market trading at new all-time highs, institutions still find enough reason to buy more enormous stakes in three stocks.
Via
MarketBeat
Hims & Hers Stock Dropped: Here's What You Need to Know
October 24, 2024
The GLP-1 drama continues at Hims & Hers.
Via
The Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
October 23, 2024
Via
Benzinga
Exposures
Product Safety
Decoding 6 Analyst Evaluations For Hims & Hers Health
October 21, 2024
Via
Benzinga
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
October 21, 2024
From
Hims & Hers
Via
Business Wire
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
October 21, 2024
Via
Benzinga
What Is Going On With Hims & Hers Stock?
October 11, 2024
Big GLP-1 news could have an impact.
Via
The Motley Fool
Why Hims & Hers' Incredible Growth Will Continue
October 18, 2024
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.
Via
The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
October 16, 2024
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide.
Via
Investor's Business Daily
Exposures
Product Safety
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
October 14, 2024
From
Hims & Hers
Via
Business Wire
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
October 14, 2024
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own...
Via
Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
October 14, 2024
An industry group sued the FDA, claiming tirzepatide remains in shortage.
Via
Investor's Business Daily
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Where Does Hims & Hers Stock Go From Here?
October 12, 2024
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
Via
The Motley Fool
Exposures
Product Safety
2 Incredibly Cheap Growth Stocks to Buy Right Now
October 12, 2024
Look beyond the stock price at the business when shares are volatile.
Via
The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
October 12, 2024
Consistently investing even moderate sums can grow your portfolio with time.
Via
The Motley Fool
Top 3 Stocks with Explosive Call Option Activity: What to Watch
October 10, 2024
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree
Via
MarketBeat
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
October 08, 2024
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment.
Via
Benzinga
Exposures
Product Safety
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
October 08, 2024
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
October 08, 2024
Growth for its GLP-1 weight loss drugs continues to be robust.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
Via
Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
October 07, 2024
Via
Benzinga
Hims & Hers Health Stock Is Rising Monday: What's Going On?
October 07, 2024
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this week.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.